NO20076467L - Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner - Google Patents

Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner

Info

Publication number
NO20076467L
NO20076467L NO20076467A NO20076467A NO20076467L NO 20076467 L NO20076467 L NO 20076467L NO 20076467 A NO20076467 A NO 20076467A NO 20076467 A NO20076467 A NO 20076467A NO 20076467 L NO20076467 L NO 20076467L
Authority
NO
Norway
Prior art keywords
hiv
derivative
tat
proteins
protein
Prior art date
Application number
NO20076467A
Other languages
English (en)
Inventor
Claudine Bruck
Stephane Andre Georges Godart
Martine Marchand
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076467(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20076467L publication Critical patent/NO20076467L/no
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfinnelsen tilveiebringer (a) et HIV-Tat-protein eller derivat derav koblet til enten (i) en fusjonspartner eller (ii) et HTV Nef-protein eller derivat derav; eller (b) et HTV Nef-protein eller derivat derav koblet til enten (i) en fusjonspartner eller (ii) et HIV-Tat-protein eller derivat derav; eller (c) et HTV-Nef-protein eller derivat derav koblet til et HIV-Tat-protein eller derivat derav og en fusjonspartner. Oppfinnelsen tilveiebringer videre en nukleinsyre som koder for et slikt protein og en vertscelle, slik som Pichia Pastoris, transformert med den før nevnte nukleinsyren.
NO20076467A 1997-09-26 2007-12-14 Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner NO20076467L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine
PCT/EP1998/006040 WO1999016884A1 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (1)

Publication Number Publication Date
NO20076467L true NO20076467L (no) 2000-05-18

Family

ID=10819735

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001508A NO328824B1 (no) 1997-09-26 2000-03-23 Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert.
NO20076467A NO20076467L (no) 1997-09-26 2007-12-14 Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20001508A NO328824B1 (no) 1997-09-26 2000-03-23 Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert.

Country Status (28)

Country Link
EP (1) EP1015596B2 (no)
JP (2) JP2001518300A (no)
KR (1) KR100554487B1 (no)
CN (1) CN1188519C (no)
AR (2) AR017147A1 (no)
AT (1) ATE338128T1 (no)
AU (1) AU746564B2 (no)
BR (1) BR9812547A (no)
CA (1) CA2305013C (no)
CO (1) CO4810339A1 (no)
CZ (1) CZ302878B6 (no)
DE (1) DE69835756T3 (no)
DK (1) DK1015596T4 (no)
ES (1) ES2272012T5 (no)
GB (1) GB9720585D0 (no)
HK (1) HK1030431A1 (no)
HU (1) HUP0004896A3 (no)
IL (1) IL135102A0 (no)
NO (2) NO328824B1 (no)
NZ (1) NZ503482A (no)
PL (1) PL195243B1 (no)
PT (1) PT1015596E (no)
SA (1) SA98190877B1 (no)
SI (1) SI1015596T2 (no)
TR (1) TR200000864T2 (no)
TW (1) TW499436B (no)
WO (1) WO1999016884A1 (no)
ZA (1) ZA988789B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
JP2002541786A (ja) * 1999-04-12 2002-12-10 モデックス テラピューティク ソシエテ アノニム 遺伝子治療における使用のための一過性不死化細胞
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CZ20022643A3 (cs) * 2000-01-31 2003-02-12 Smithkline Beecham Biologicals S. A. Farmaceutický prostředek
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101196178B1 (ko) * 2002-05-16 2012-11-01 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IN2014DN06624A (no) 2005-10-18 2015-07-10 Univ Colorado
KR101662574B1 (ko) 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
CA2716928C (en) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
AU2009246876B2 (en) 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2313496T3 (en) 2008-07-21 2014-12-15 Taiga Biotechnologies Inc Anukleære differentiated cells, and method for preparation thereof
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
WO2010051367A1 (en) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
CN102575232B (zh) 2009-05-29 2015-07-22 宾夕法尼亚大学托管会 猿腺病毒41及其应用
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2708561A4 (en) * 2011-03-15 2014-09-24 Univ Yonsei Iacf BIO-PIN
CA2873509A1 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) * 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
PT3142750T (pt) 2014-05-13 2020-09-22 Univ Pennsylvania Composições que compreendem aav expressando construções de anticorpos duplos e suas utilizações
ES2865392T7 (es) * 2015-04-16 2022-09-07 The Research Foundation For The State Univ Of New York Univ At Buffalo Nanoestructuras que comprenden conjugados de porfirina de cobalto-fosfolípido y etiquetas de polihistidina
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
EP0656950B1 (en) * 1992-08-21 1998-11-04 Biogen, Inc. Tat-derived transport polypeptides
DE69434469T2 (de) * 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
DE69835756T3 (de) 2010-09-30
AR080331A2 (es) 2012-03-28
EP1015596B2 (en) 2010-04-14
DE69835756D1 (de) 2006-10-12
ES2272012T5 (es) 2010-07-06
IL135102A0 (en) 2001-05-20
KR100554487B1 (ko) 2006-03-03
NZ503482A (en) 2001-09-28
CZ302878B6 (cs) 2012-01-04
PL339432A1 (en) 2000-12-18
DK1015596T3 (da) 2007-01-02
DE69835756T2 (de) 2007-09-13
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
AU746564B2 (en) 2002-05-02
WO1999016884A1 (en) 1999-04-08
EP1015596A1 (en) 2000-07-05
CA2305013A1 (en) 1999-04-08
EP1015596B1 (en) 2006-08-30
TR200000864T2 (tr) 2000-08-21
SI1015596T2 (sl) 2010-07-30
TW499436B (en) 2002-08-21
ATE338128T1 (de) 2006-09-15
PL195243B1 (pl) 2007-08-31
SI1015596T1 (sl) 2007-02-28
GB9720585D0 (en) 1997-11-26
CN1188519C (zh) 2005-02-09
CZ20001091A3 (cs) 2000-09-13
CN1279718A (zh) 2001-01-10
AU1025599A (en) 1999-04-23
JP2009213492A (ja) 2009-09-24
HUP0004896A1 (hu) 2001-04-28
DK1015596T4 (da) 2010-07-12
SA98190877B1 (ar) 2006-09-10
KR20010024287A (ko) 2001-03-26
CO4810339A1 (es) 1999-06-30
BR9812547A (pt) 2000-07-25
HUP0004896A3 (en) 2003-05-28
AR017147A1 (es) 2001-08-22
ZA988789B (en) 2000-03-29
NO328824B1 (no) 2010-05-25
JP2001518300A (ja) 2001-10-16
HK1030431A1 (en) 2001-05-04
CA2305013C (en) 2008-04-08
ES2272012T3 (es) 2007-04-16
NO20001508L (no) 2000-05-18

Similar Documents

Publication Publication Date Title
NO20076467L (no) Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DK0765394T3 (da) Oprensede Myceliopthora-laccaser og nukleinsyrer der koder for disse
DK447688D0 (da) Fremgangsmaade til isolering af basiske proteiner fra proteinblandinger
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
DK1121382T3 (da) Interferon-beta-fusionsproteiner og deres anvendelser
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
DE3853922D1 (de) Aminosäurederivate als Amphotere.
SE9901379D0 (sv) Receptor structures
BR9906927A (pt) Proteìnas de neisseria meningitidis
NO20011842L (no) Stabile, konsentrerte insulinpreparater for pulmonal avlevering
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
DK0909562T3 (da) Injektionspræparat indeholdende en lipid A analog og fremgangsmåde til fremstilling deraf
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
CY1109207T1 (el) Διαδικασια εχινοκανδινης
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
NO980566L (no) Allergen-XCD32 fusjonsproteiner
DE60118935D1 (de) Dna & protein bindende miniatur proteine
DK1066328T3 (da) Kimært protein, der indeholder en intramolekylær chaperon-lignende sekvens, og dets anvendelse til insulinproduktion
DK312787D0 (da) Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne
DK0864653T3 (da) Fremgangsmåde til fremstilling af 4-(4-(4-(hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-alfa,alfa-dimethylphenyleddikesyre og phosphorylerede derivater deraf
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum